Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Trends and disparities in mortality from malignant neoplasms of digestive system and renal failure in the United States, 1999-2023.

Nandni Kumari, Kinza Raza, Muhammad Sarim Azad Khan et al. Jun 01, 2026 pp. 11135-11135 10.1200/jco.2026.44.16_suppl.11135

11135 Background: Malignancies of the digestive system represent a substantial global health burden, often exacerbated by...

Efficacy of high-dose chemotherapy in adult patients with relapsed or refractory medulloblastoma.

Nurlan Mammadzada, Berkan Karadurmuş, Esmanur Kaplan Tüzün et al. Jun 01, 2026 pp. 2087-2087 10.1200/jco.2026.44.16_suppl.2087

2087 Background: Adult medulloblastoma (MB) is rare, and there is no standard salvage approach for relapsed or refractory...

Machine learning–integrated transcriptomic clustering for prognostic stratification in epithelioid pleural mesothelioma.

Mario Occhipinti, Arianna Rigamonti, Paolo Ambrosini et al. Jun 01, 2026 pp. 8051-8051 10.1200/jco.2026.44.16_suppl.8051

8051 Background: Survival outcomes in pleural mesothelioma (PM), particularly within epithelioid PM (ePM), are heterogeneo...

Cell-free DNA methylation profile–based fusion epigenotyping to enhance <i>ALK</i> fusion detection in NSCLC patients.

Laura Tung, Anton Valouev, Justin Odegaard et al. Jun 01, 2026 pp. 3070-3070 10.1200/jco.2026.44.16_suppl.3070

3070 Background: Short read lengths in next-generation sequencing and targeted panel probe design pose challenges to fusio...

The glucocorticoid toxicity index: Assessing corticosteroid toxicity in patients with immune-related adverse events from cancer immunotherapy for solid tumors.

Jarushka Naidoo, Darren Dorrell, Seid Hamzic et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24194

e24194 Background: Immune checkpoint inhibitors (ICIs) cause immune-related adverse events (irAEs) requiring systemic cort...

Primary squamous cell carcinoma of the pancreas: A SEER-based analysis.

Alaa Mahmoud, Khaled M. El-Husseiny, Ibrahim Hassan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16389

e16389 Background: Primary squamous cell carcinoma of the pancreas (PSCCP) is an exceedingly rare malignancy with a poor p...

Quality of life among caregivers of patients with breast cancer in Mexico: A multicenter cross-sectional survey using the Caregiver Quality of Life Index–Cancer (CQOLI-C).

Carlos A. Gonzalez-Assad, Alejandra Platas, Ana Platas et al. Jun 01, 2026 pp. 11103-11103 10.1200/jco.2026.44.16_suppl.11103

11103 Background: Family caregivers of patients with breast cancer (BC) often experience emotional, physical, social, and...

Healthcare provider use of a community-based narrative resource to support psychosocial care in AYA oncology.

Nick Giallourakis, Kayla Fulginiti, Lisa Orr et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13570

e13570 Background: Adolescents and young adults (AYAs) with cancer experience heightened psychosocial distress, including...

Diabetes-related mortality among cancer survivors: A population-based cohort study.

Joseph Shehata, Abanoub Soliman, Kerolos Emad Naguib Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23068

e23068 Background: As cancer survival improves, noncancer causes of death have taken the attention. Diabetes mellitus is c...

Who gets access? National discrepancies in clinical trial enrollment among patients with brain metastases.

Manuela Jaramillo, Zouina Sarfraz, Fatma Nihan Akkoc Mustafayev et al. Jun 01, 2026 pp. 1655-1655 10.1200/jco.2026.44.16_suppl.1655

1655 Background: Patients with brain metastases (BM) have historically been underrepresented in clinical trials. Contempor...

Incretin-based therapies and all-cause mortality and progression to multiple myeloma in patients with MGUS and type 2 diabetes: A real-world cohort study.

Yousef Ateiwi, Mohammmad Amer Al Tamimi, Leen Alkuttob et al. Jun 01, 2026 pp. 7572-7572 10.1200/jco.2026.44.16_suppl.7572

7572 Background: Monoclonal gammopathy of undetermined significance (MGUS) progresses to multiple myeloma (MM) at an estim...

Addressing geographic disparities in cancer care: An examination of the contributions of international medical graduates (IMGs).

Nazli Dizman, M. Kelsey Kirkwood, Laura A. Levit et al. Jun 01, 2026 pp. 1516-1516 10.1200/jco.2026.44.16_suppl.1516

1516 Background: IMGs comprise 38% of the US hematology and medical oncology workforce according to the Association of Ame...

Systemic therapy–associated differences in intracranial disease in metastatic prostate cancer: A real-world study.

Nikhila Sampath Kumar, Rohan Seth, Shi-Ming Tu Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17080

e17080 Background: Brain or leptomeningeal involvement in prostate cancer has historically been rare. As systemic therapie...

Integrated clinical and molecular characterization of WNT pathway alterations in metastatic castration-resistant prostate cancer (mCRPC) liver metastases (mets).

Elise Y. Cai, Li Zhang, Nonna Shakhnazaryan et al. Jun 01, 2026 pp. 5048-5048 10.1200/jco.2026.44.16_suppl.5048

5048 Background: mCRPC patients (pts) with liver mets (LM) have an aggressive clinical course and poor response to establi...

Reassessing neutropenic vs liberalized diets in post-chemotherapy and hematopoietic stem cell transplantation patients: An updated meta-analysis.

Muhammad Asjid, Faseeh Haider, Arsalan Ahmed et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18571

e18571 Background: Neutropenia following high-dose chemotherapy or hematopoietic stem cell transplantation (HSCT) in patie...

Trust, ethics, and patient engagement in clinical research: Findings from the LACOG 1123 ASTRAL survey in Brazil.

Gisah Guilgen, Debora De Melo Gagliato, Angelica Nogueira Rodrigues et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23171

e23171 Background: Trust, ethical understanding, and engagement are critical determinants of successful and equitable clin...

Proteomic profiling of circulating tumor cells (CTCs) in metastatic urothelial cancer (mUC) as associated with upregulation of EGFR, HER2, and B7-H3 in patients (pts) progressing on enfortumab vedotin (EV) plus pembrolizumab.

Wadih Issa, Navneet Kaur, Qinhan Zhou et al. Jun 01, 2026 pp. 4580-4580 10.1200/jco.2026.44.16_suppl.4580

4580 Background: Pts with mUC have poor prognosis, and while EV/pembro have improved outcomes, therapeutic targets arising...

Long-term survival update of TRUCE-01: A phase 2 study of preoperative tislelizumab combined with low-dose nab-paclitaxel for muscle-invasive bladder cancer (MIBC).

Zhouliang Wu, Yunkai Qie, Chong Shen et al. Jun 01, 2026 pp. 4585-4585 10.1200/jco.2026.44.16_suppl.4585

4585 Background: The TRUCE-01 study (NCT04730219) previously met its primary endpoint, demonstrating that preoperative tis...

Research on the development and application of bundled care protocols for radiation dermatitis in nasopharyngeal cancer patients.

Jia Cao, Guoyan Cheng, Hualing Feng et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18123

e18123 Background: To develop a bundled care protocol for radiation dermatitis in patients with nasopharyngeal carcinoma (...

Cancer-associated sepsis hospitalizations: Outcomes, inequities, and palliative care—National Inpatient Sample analysis (2016–2022).

Harsha Pattnaik, Heng Jiang, Christopher Poletes et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23097

e23097 Background: Among patients with cancer, sepsis is a leading cause of hospitalization and mortality. Data on clinica...

Overall survival in veterans with metastatic hormone sensitive prostate cancer by initial therapy and STRATOS-P somatic tumor classification.

Robert Wilson, Abigail Chu, Molly Wynveen et al. Jun 01, 2026 pp. 5105-5105 10.1200/jco.2026.44.16_suppl.5105

5105 Background: The STRATOS-P somatic tumor classification stratifies patients with metastatic hormone-sensitive prostate...

Final results and correlative analysis of entinostat (E) plus pembrolizumab (P) in patients (Pts) with metastatic melanoma (MM) previously treated with anti–PD-(L)1 therapy (Tx).

Stergios J. Moschos, Meghan J. Mooradian, Melissa Lynne Johnson et al. Jun 01, 2026 pp. 9522-9522 10.1200/jco.2026.44.16_suppl.9522

9522 Background: PD(L)1 inhibitors have transformed MM tx, yet several pts experience resistance. Preclinical data suggest...

Impact of para-cervical boost with volumetric modulated arc therapy on local control in locally advanced cervical cancer: A single-arm study.

Yuanjing Wang, Ming Wang, Yin Lv Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17516

e17516 Background: Concurrent chemoradiation is the standard treatment for locally advanced cervical cancer (LACC). Treatm...

The CO.33/BATTMAN trial: A phase 3 randomized study of botensilimab + balstilimab versus best supportive care in chemorefractory unresectable colorectal adenocarcinoma that is not dMMR/MSI-H.

Jonathan M. Loree, Jeanne Tie, Emmanuelle Samalin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3676

TPS3676 Background: Despite significant progress and newly approved agents, metastatic colorectal cancer (mCRC) has limite...

Efficacy and safety of hetrombopag for secondary prevention of chemotherapy-induced thrombocytopenia in patients with gynecologic malignancies: A single-arm phase 2 trial.

Miao-fang Wu, Jing Li, Dongyan Wang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24185

e24185 Background: Chemotherapy-induced thrombocytopenia (CIT) is common in patients (pts) with gynecologic malignancies a...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page